申请人:Teijin Limited
公开号:US04022891A1
公开(公告)日:1977-05-10
Novel 1.alpha., 24-dihydroxycholecalciferol and derivatives thereof which are useful with reduced side-effects for the treatment of abnormal metabolism of calcium and phosphorus caused by liver failure, renal failure, gastrointestinal tract failure and parathyroid failure, and related bone diseases. Preparation of the novel 1.alpha., 24-dihydroxycholecalciferol and their derivatives starts from 1.alpha., 24-dihydroxycholesterol prepared by reacting 1.alpha., 2.alpha.-epoxy-24-keto-cholesta-4,6-dien-3-one with an alkali metal and a proton donor in the presence of liquid ammonia or a liquid amine. Reaction of the 1.alpha., 24-dihydroxycholesterol with an allylic brominating agent, followed by contacting with a dehydrobrominating agent, affords 1.alpha.,3.beta., 24-trihydroxycholesta-5,7-diene derivative, which can then be converted to 1.alpha., 24-dihydroxycholocalciferol by ultraviolet irradiation in a organic solvent, followed by isomerization. Processes are also provided for separating 1.alpha., 24-dihydroxycholesterol into an (S)-epimer and an (R)-epimer, and also for separating at least one of 1.alpha., 3.beta., 24(S)-and 1.alpha., 3.beta., 24(R)-trihydroxycholesta-5,7-dienes from trihydroxycholesta-4,6-diene.
1.alpha., 24-二羟基胆钙化醇及其衍生物,对于由肝功能衰竭、肾功能衰竭、胃肠道功能衰竭和甲状旁腺功能衰竭引起的钙磷代谢异常以及相关骨病的治疗具有减少副作用的作用。制备这种新型1.alpha., 24-二羟基胆钙化醇及其衍生物的方法是从通过在液氨或液胺存在下,将1.alpha., 2.alpha.-环氧-24-酮基-胆甾-4,6-二烯-3-酮与碱金属和质子给体反应制备的1.alpha., 24-二羟基胆固醇开始。将1.alpha., 24-二羟基胆固醇与烯丙基溴化剂反应,然后与脱溴化剂接触,得到1.alpha.,3.beta., 24-三羟基胆甾-5,7-二烯衍生物,然后可以通过在有机溶剂中紫外辐射,随后异构化,将其转化为1.alpha., 24-二羟基胆钙化醇。还提供了将1.alpha., 24-二羟基胆固醇分离成(S)-对映体和(R)-对映体的方法,以及将1.alpha., 3.beta., 24(S)-和1.alpha., 3.beta., 24(R)-三羟基胆甾-5,7-二烯中的至少一种与三羟基胆甾-4,6-二烯分离的方法。